Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 16/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 16/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 16/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080327 | 0.90 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7080344 | 0.90 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7079297 | 0.87 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7077166 | 0.85 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7077163 | 0.85 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7079569 | 0.83 | MAPK13 (0.72) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7082261 | 0.83 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11TP53 | |
| SCHEMBL2201099 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6652753 | 0.81 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7196493 | 0.79 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | claimed |
| WO-2002083622-A2 | NOVEL AMINOPHENYL KETONE DERIVATIVES | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | claimed |
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | disclosed |
| WO-2002083622-A2 | NOVEL AMINOPHENYL KETONE DERIVATIVES | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | MAPKAPK2, MAP3K2, MAP3K1 | MAPK14 28/4885MAPK13 33/4885MAPK12 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.